Search Results

Purple Biotech Ltd. today announced a research collaboration with Mor Research Applications (Mor), the technology transfer subsidiary of Clalit Healthcare Services (Clalit).

RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform signed a contract research agreement with SEKISUI CHEMICAL CO., LTD..

The Maryland Stem Cell Research Commission announces the release of Requests for Applications for the Maryland Stem Cell Research Fund’s first funding cycle of fiscal year 2025.

Sentrex Health Solutions Inc., a leading provider of specialty healthcare services in Canada, is excited to announce the acquisition of PerCuro Clinical Research Ltd.—one of Canada’s premier providers of infusion services, clinical research, and advanced nursing care.

Ono Pharmaceutical Co., Ltd. informed that it has started a new collaboration with BioMed X on cancer immunotherapies and has been inviting researchers who are interested in this research project via BioMed X.

ImmunoPrecise Antibodies Ltd., a leader in AI-driven biotherapeutic research and technology, announces that its subsidiary, BioStrand, has been honored with the prestigious 2024 Impact Award, sponsored by InterSystems.

- Company listed in Research and Markets’ announcement and description of new research report on the U.S. Breast Cancer Screening and Diagnostic Market- - “U.S. breast cancer screening and diagnostic [device] market was valued at $1.55 billion in 2024 and is anticipated to reach $2.34 billion by the end of 2030, at a CAGR of 7.05% during the forecast period 2024-20301"- -Report supports Company’s regulatory strategy for IzoView Breast CT, reinforces high demand for new breast imaging modalities, strengthens the potential for rapid market adoption and significant market share -

BioLineRx Ltd. today announced a multi-center Phase 1 clinical trial sponsored by St. Jude Children’s Research Hospital, Inc. to evaluate motixafortide for the mobilization of CD34+ hematopoietic stem cells (HSCs) used in the development of gene therapies for patients with sickle cell disease (SCD).